Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Instituto Nacional de Salud Pública
2008
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876464666730823680 |
|---|---|
| author | Oscar Andrés-Gamboa |
| author_facet | Oscar Andrés-Gamboa |
| contents | Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia Oscar Andrés-Gamboa Liliana Chicaíza Mario García-Molina Jorge Díaz Mauricio González Raúl Murillo Mónica Ballesteros Ricardo Sánchez Salud cost Colombia mass screening benefit analysis Uterine cervical neoplasms To assess cost-effectiveness of conventional cytology and HPV DNA testing for cervical-cancer screening in Colombia. Material and Methods: The National Cancer Institute of Colombia (NCIC) in 2007 developed a Markov model on the natural history of cervical cancer; no screening, conventional cytology, and HPV DNA testing were compared. Only direct costs were used. Outcomes comprise cervical cancer mortality, years of life saved, and lifetime costs. Discounted incremental cost-effectiveness ratios were estimated and sensitivity analyses were conducted for key parameters. Results: Depending on the screening strategy a 69-81% mortality reduction might be expected. The HPV DNA testing every five years is a cost-effective strategy (Incremental Cost-Effectiveness Ratio (ICER): USD$44/YLS) if the costper test is under USD$31. The effectiveness was sensitive to coverage and primarily to follow-up. Conclusions: HPV DNA testing is a cost-effective alternative for screening in Colombia. Not only high coverage but high follow-up rates are critical for successful screening programs. 2008 artículo científico 0036-3634 https://www.redalyc.org/articulo.oa?id=10611147002 en http://www.redalyc.org/revista.oa?id=106 Salud Pública de México application/pdf Instituto Nacional de Salud Pública Salud Pública de México (México) Num.4 Vol.50 |
| format | Artículo científico |
| id | redalyc_10611147002 |
| institution | Redalyc |
| language | en |
| publishDate | 2008 |
| publisher | Instituto Nacional de Salud Pública |
| spellingShingle | Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia Oscar Andrés-Gamboa Salud cost Colombia mass screening benefit analysis Uterine cervical neoplasms Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia Oscar Andrés-Gamboa Liliana Chicaíza Mario García-Molina Jorge Díaz Mauricio González Raúl Murillo Mónica Ballesteros Ricardo Sánchez Salud cost Colombia mass screening benefit analysis Uterine cervical neoplasms To assess cost-effectiveness of conventional cytology and HPV DNA testing for cervical-cancer screening in Colombia. Material and Methods: The National Cancer Institute of Colombia (NCIC) in 2007 developed a Markov model on the natural history of cervical cancer; no screening, conventional cytology, and HPV DNA testing were compared. Only direct costs were used. Outcomes comprise cervical cancer mortality, years of life saved, and lifetime costs. Discounted incremental cost-effectiveness ratios were estimated and sensitivity analyses were conducted for key parameters. Results: Depending on the screening strategy a 69-81% mortality reduction might be expected. The HPV DNA testing every five years is a cost-effective strategy (Incremental Cost-Effectiveness Ratio (ICER): USD$44/YLS) if the costper test is under USD$31. The effectiveness was sensitive to coverage and primarily to follow-up. Conclusions: HPV DNA testing is a cost-effective alternative for screening in Colombia. Not only high coverage but high follow-up rates are critical for successful screening programs. 2008 artículo científico 0036-3634 https://www.redalyc.org/articulo.oa?id=10611147002 en http://www.redalyc.org/revista.oa?id=106 Salud Pública de México application/pdf Instituto Nacional de Salud Pública Salud Pública de México (México) Num.4 Vol.50 |
| title | Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia |
| topic | Salud cost Colombia mass screening benefit analysis Uterine cervical neoplasms |
| url | https://www.redalyc.org/articulo.oa?id=10611147002 |